Keeping Weight Off with Mazdutide and Lifestyle Support in People with Obesity
Tests mazdutide, lifestyle support, or both for keeping weight off in adults with obesity.
Plain-language title generated from the registry record
Registry title: ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
Key facts
- Where
- Chongqing, Fuzhou, Hangzhou, Luzhou, Nanjing, Shanghai, Suzhou, Wenzhou, Wuhan, and Xiamen, ChinaSee the 13 sites
Where in China
- The Second Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaTaking people
- Fujian Provincial Hospital Affiliated to Fuzhou UniversityFuzhou, ChinaTaking people
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
- The Affiliated Hospital of Southwest Medical UniversityLuzhou, ChinaTaking people
- Nanjing First Hospital, Nanjing Medical UniversityNanjing, ChinaTaking people
- Huadong Hospital, Fudan UniversityShanghai, ChinaTaking people
- Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
- Shanghai Tenth People's Hospital, School of Medicine, Tongji UniversityShanghai, ChinaTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
- The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical UniversitySuzhou, ChinaTaking people
- The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
- Zhongnan Hospital of Wuhan UniversityWuhan, ChinaTaking people
- The First Affiliated hospital of Xiamen UniversityXiamen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Zhongshan Hospital
- Trial code
- NCT07517042
- Record updated
- 22 October 2026
- Original description
Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance.Read full original descriptionShow less
Achieving Sustained Weight Control Via Exercise, Nutrition & Drugs (Mazdutide) (ASCEND- 1 Trial)
Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance.
This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.
Inclusion: Adult men or women aged 18 years or older; Simple obesity, defined as a body mass index (BMI) of 28.0-45.0 kg/m²; Able and willing to provide written informed consent.
Exclusion: Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other serious infectious or systemic diseases; Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months; Severe gastrointestinal diseases, or a history of gastrointestinal resection surgery within the past year; Acute or chronic pancreatitis, gallbladder disease, or pancreatic injury; Obesity secondary to other causes, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, or acromegaly; drug-induced obesity, such as obesity related to the use of antipsychotic agents or glucocorticoids; Current use of other weight-loss medications or a history of bariatric surgery; Inability to complete a 2-year follow-up due to health conditions, relocation, or other reasons; Any other condition deemed by the investigator to make the participant unsuitable for participation in the study; Severe hepatic impairment (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >3 times the upper limit of normal), severe renal impairment, or end-stage renal disease (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m²); Previously diagnosed diabetes mellitus or current use of glucose-lowering medications; Current smoker or habitual smoking within the past 3 months; Pregnant or breastfeeding women, or women planning pregnancy during the study period.